Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

NHS is rolling out two types of testing (genetic testing for monogenic diabetes and placental growth factor (PLGF) testing to rule out pre-eclampsia)

In August 2021, NHS announced rolling out genetic testing for monogenic diabetes and placental growth factor (PLGF) testing to rule out pre-eclampsia.

The NHS Long Term Plan is committed to increasing access to genomic testing and improving diabetes care across the country. In line with it, NHS launched a new program to support Trusts across the country to help improve the identification of monogenic diabetes. The program includes rolling out the genetic test, as well as a national virtual training package at the Royal Devon and Exeter NHS Foundation Trust, and practical support provided by 15 specialist genetic diabetes nurses.

Monogenic diabetes is caused by a mutation in a single gene that is passed on from an affected parent to their child. It is managed pharmacologically (pills) or by diet instead of insulin therapy. The test can also identify whether children have inherited the affected gene and will develop monogenic diabetes, typically before the age of thirty.

Placental growth factor (PLGF) blood testing is being rolled out as part of the NHS Long Term Plan's ambitions to invest in more world-class treatments and cutting-edge technologies. The test provides a quick diagnosis of pre-eclampsia and significantly reduces the need for hospital trips, freeing up clinics and staff workload. Three-quarters of maternity units are using the test already, and the test will be available across all of England within the next two years.

See the full details on testing for monogenic diabetes here and PLGF here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).